Results 191 to 200 of about 86,629 (276)

Peripheral Neuropathy Associated With Proteasome Inhibitors and Immunomodulatory Drugs: A Pharmacovigilance Disproportionality Analysis Using VigiBase. [PDF]

Pharmacol Res Perspect
Braga LP, de Pádua CAM, da Costa IHF, de Miranda Drummond PL, de Souza PHC, Fonseca LB, Rodrigues MA, Malta JS, Reis AMM.   +8 more
europepmc   +1 more source

Functional precision approach in patients with very high risk acute lymphoblastic leukaemia in India: a single-centre cohort study. [PDF]

Lancet Reg Health Southeast Asia
Sidhu J, Chakraborty A, Das P, Steffen FD, Kundu S, Basu S, Tarafdar B, Dey T, Kar A, Biswas M, Das A, Sivadasan N, Dasgupta P, Ghara N, Bornhauser B, Bourquin JP, Krishnan S, Saha V.   +17 more
europepmc   +1 more source

A bortezomib resistance-related gene signature predicts prognosis, with ARID5B downregulation associated with poor overall survival in multiple myeloma. [PDF]

Discov Oncol
Ding Y, Xiao M, Zhu J, Jiao X, Guo J, Shudao X, Wang J.   +6 more
europepmc   +1 more source

Severe pulmonary complication after bortezomib treatment for multiple myeloma [PDF]

, 2006
James E. Boyer, Reema Batra, João L. Ascensão, Geraldine P. Schechter   +3 more
openalex   +1 more source

Clinical outcomes of lenalidomide, bortezomib, and dexamethasone in multiple myeloma patients. [PDF]

Am J Transl Res
Yu L, Ren L, Hou Z, Yang Y, Zhang K.
europepmc   +1 more source

Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia [PDF]

, 2014
T. Morita, Tomotaka Ugai, Tetsuya Tanimoto, Kosei Matsue   +3 more
openalex   +1 more source

Differential molecular mechanisms of bortezomib sensitization to rhTRAIL in non-small cell lung cancer cell lines. [PDF]

Explor Target Antitumor Ther
Kochany P, Stegehuis JH, de Wilt LHAM, Jansen G, de Jong S, Peters GJ, Kruyt FAE.   +6 more
europepmc   +1 more source

Bortezomib overcomes TRAIL resistance in Burkitt's lymphoma by enhancing apoptosis via reactive oxygen species-mediated DR5 upregulation and MAPK pathway activation. [PDF]

Oncol Lett
Chen J, You Y, Zhao W, Zhou Y, Pu S, Bai X, Yang P, Li M.   +7 more
europepmc   +1 more source

Correction: Enhanced proteasomal activity is essential for long term survival and recurrence of innately radiation resistant residual glioblastoma cells. [PDF]

Oncotarget
Rajendra J, Datta KK, Farooqee SBUD, Thorat R, Kumar K, Gardi N, Kaur E, Nair J, Salunkhe S, Patkar K, Desai S, Goda JS, Moiyadi A, Dutt A, Venkatraman P, Gowda H, Dutt S.   +16 more
europepmc   +1 more source

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma [PDF]

, 2009
Martin Kropff, Peter Liebisch, Stefan Knop, Katja Weisel, Hannes Wand, Claudia-Nanette Gann, Wolfgang E. Berdel, H. Einsele, Herrmann Einsele   +8 more
openalex   +1 more source